Temozolomide for malignant gliomas in British Columbia: A population-based cost-effectiveness analysis

Journal of Oncology Pharmacy Practice

Volumn 10, Issue 4, 2004, Pages 201-209

  Greanya, E D ^a   Taylor, S C M ^b   Hu, F ^b   Barnett, J ^b   Thiessen, B ^b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

Astrocytoma; Cost effectiveness; Glioma; Lomustine; Temozolomide

Indexed keywords

LOMUSTINE; TEMOZOLOMIDE;

ADULT; AGED; ARTICLE; CANADA; CANCER SURVIVAL; COHORT ANALYSIS; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG RESPONSE; FEMALE; GLIOBLASTOMA; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SENSITIVITY ANALYSIS; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE;

EID: 13444272122     PISSN: 10781552     EISSN: None     Source Type: Journal    
DOI: 10.1191/1078155204jp138oa     Document Type: Article

References (22)

1. Cochrane Glioma Meta-analysis Trialists (GMT) Group. Chemotherapy for high-grade glioma. Cochrane Database of Systematic Reviews. 2004; 1.
2. BC Cancer Agency, Provincial Health Services Authority. Cancer Management Guidelines - Neuro-Oncology. 2004 Feb. Available: http://www.bccancer.bc.ca (accessed 07 May 2004).
3. Hofer S, Herrmann R. Chemotherapy for malignant brain tumors of astrocytic and oligodendroglial lineage. J Cancer Res Clin Oncol 2001; 127: 91-95.
4. Quinn JA, Reardon DA, Friedman AH, Rich JN, Sampson JH, Provenzale JM, McLendon RE, Gururangan S, Bigner DD, Herndon JE II, Avgeropoulos N, Finlay J, Tourt-Uhlig S, Affronti ML, Evans B, Stafford-Fox V, Zaknoen S, Friedman HS. Phase II trial of temozolomide in patients with progressive low-grade glioma. J Clin Oncol 2003; 21: 646-51.
5. Parney IF, Chang SM. Current chemotherapy for glioblastoma. Cancer J 2003; 9: 149-56.
6. Chang SM, Theodosopoulos P, Lamborn K, Malec M, Rabbitt J, Page M, Prados MD. Temozolomide in the treatment of recurrent malignant glioma. Cancer 2004; 100: 605-11.
7. Dinnes J, Cave C, Huang S, Milne R. A rapid and systematic review of the effectiveness of temozolomide for the treatment of recurrent malignant glioma. Br J Cancer 2002; 86: 501-505.
8. Brandes AA, Ermani M, Basso U, Paris MK, Lumachi F, Berti F, Amirta P, Gardiman M, Iuzzolino P, Turazzi S, Monfardini S. Temozolomide in patients with glioblastoma at second relapse after first line nitrosoureaprocarbazine failure: a phase II study. Oncology 2002; 63: 38-41.
9. Yung WKA, Prados MD, Yaya-Tur R, Rosenfeld SS, Brada M, Friedman HS, Albright R, Olson J, Chang SM, O'Neill AM, Friedman AH, Bruner J, Yue N, Dugan M, Zaknoen S, Levin VA. Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. J Clin Oncol 1999; 17: 2762-71.
10. Gaya A, Rees J, Greenstein A, Stebbing J. The use of temozolomide in recurrent malignant gliomas. Cancer Treat Rev 2002; 28: 115-20.
11. Bower M, Newlands ES, Bleehan NM, Brada M, Begent RJH, Calvert H, Colquhoun I, Lewis P, Brampton MH. Multicentre CRC phase II trial of temozolomide in recurrent or progressive high grade glioma. Cancer Chemother Pharmacol 1997; 40: 484-88.
12. Brada M, Hoang-Xuan K, Rampling R, Dietrich PY, Dirix LY, MacDonald D, Heimans JJ, Zonnerberg BA, Bravo-Marques JM, Henriksson R, Stupp R, Yue N, Bruner J, Dugan M, Rao S, Zaknoen S. Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse. Ann Oncol 2001; 12: 259-66.
13. Brandes AA, Ermani M, Basso U, Amista P, Berti F, Scienza R, Rotilio A, Pinna G, Gardiman M, Monfardini S. Temozolomide as a second-line systemic regimen in recurrent high-grade glioma: a phase II study. Ann Oncol 2001; 12: 255-57.
14. Yung WKA, Albright RE, Olson J, Fredericks R, Fink K, Prados MD, Brada M, Spence A, Hohl RJ, Shapiro W, Glantz M, Greenberg H, Selker RG, Vick NA, Rampling R, Friedman H, Phillips P, Bruner J, Yue N, Osoba D, Zaknoen S, Levin VA. A phase II study of temozolomide versus procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer 2000; 83: 588-93.
15. Chinot OL, Honore S, Dufour H, Barrie M, Figarella-Branger D, Muracciole X, Braguer D, Martin PM, Grisoli F. Safety and efficacy of temozolomide in patients with recurrent anaplastic oligodendrogliomas after standard radiotherapy and chemotherapy. J Clin Oncol 2001; 19: 2449-55.
16. van den Bent MJ, Taphoorn MJB, Brandes AA, Menten J, Stupp R, Frenay M, Chinot O, Dros JM, van der Rijt CCD, Vecht ChJ, Allgeier A, Gorlia T. Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: The European organization for research and treatment of cancer brain tumor group study 26971. J Clin Oncol 2003; 21: 2525-28.
17. Taylor SCM, Uyeno KT, O'Reilly SE, Murphy KC, Kapty ADK. Development of a systemic therapy costing model in a provincial oncology centre. (abstract). Eur J Cancer 2000; 36 (Suppl 3): S26.
18. Taylor SCM, Chow L. Development of a pharmacoeconomics service in a provincial oncology program. (abstract). Eur J Cancer 1997; 33 (Suppl 9): S31.
19. Osoba D, Brada M, Yung WKA, Prados MD. Health-related quality of life in patients with anaplastic astrocytoma during treatment with temozolomide. Eur J Cancer 2000; 36: 1788-95.
20. Osoba D, Brada M, Yung WKA, Prados MD. Health-related quality of life in patients treated with temozolomide versus procarbazine for recurrent glioblastoma multiforme. J Clin Oncol 2000; 18: 1481-91.
21. Stupp R, Dietrich PY, Kraljevic SO, Pica A, Maillard I, Maeder P, Meuli R, Janzer R, Pizzalate G, Miralbell R, Porchet F, Regli L, de Tibolet N, Mirimanoff RO, Leyvraz S. Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol 2002; 20: 1375-82.
22. Stupp R, Mason WP, Van Den Bent MJ, Weller M, Fisher B, Taphoorn M, Brandes AA, Cairncross G, Lacombe D, Mirimanoff RO. Concomitant and adjuvant temozolomide (TMZ) and radiotherapy (RT) for newly diagnosed glioblastoma multiforme (GBM). Conclusive results of a randomized phase III trial by the EORTC Brain & RT Groups and NCIC Clinical Trials Group (abstract 2). Proc Am Soc Clin Oncol 2004; 23: 1.